Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 11
Submit an article Journal homepage
1,026
Views
36
CrossRef citations to date
0
Altmetric
Drug Evaluation

Imiglucerase and its use for the treatment of Gaucher's disease

Neal J Weinreb University Research Foundation for Lysosomal Storage Diseases, Inc., Northwest Oncology Hematology Associates PA, 8170 Royal Palm Boulevard, Coral Springs, FL 33065, USA +1 954 755 1904; +1 954 755 1910; [email protected]
, MD
Pages 1987-2000 | Published online: 16 Jul 2008

Bibliography

  • Grabowski G, Kolodny E, Weinreb N, et al. Gaucher disease: phenotypic and genetic variation. In: Scriver CR, Al Beaudet, Valle D, Slye WS, editors, The online metabolic & molecular bases of inherited disease. New York: McGraw-Hill Publishers; 2006. Chapter 146.1. Available from: http://genetics.accessmedicine.com/server-java/Arknoid/amed/mmbid/co_chapters/ch146.1_p01.html [Last accessed 31 March 2008]
  • Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
  • Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005;17:519-24
  • Edmunds T. β-Glucocerebrosidase Ceredase® and Cerezyme®. In: McGrath BM, Walsh G, editors, Directory of therapeutic enzymes. Boca Raton, FL: CRC Press; 2006. p. 117-33
  • Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosidases. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-5
  • Nilsson O, Mansson JE, Hakansson G, et al. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. Biochim Biophys Acta 1982;712:453-63
  • Langeveld M, Ghauharali KJ, Sauerwein HP, et al. Type 1 Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 2008;93:845-51
  • Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-43
  • Weinreb NJ. The bone in Gaucher disease. Eur Musculoskeletal Rev 2007;2:33-6
  • Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnoses. Arch Pediatr Adolesc Med 2006;160:603-8
  • Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, et al. Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients. Am J Obstet Gynecol 1995;172:1284-90
  • Fairley C, Zimran A, Cizmarik M, et al. Phenotypic heterogeneity of N370S homozygotes with type 1 Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. Presented at the annual meeting of the American Society of Genetics; 23 – 27 October 2007; San Diego, California. Available from: http://www.ashg.org/genetics/ashg06s/index.shtml [Last accessed 31 March 2008]
  • Maaswinkel-Mooij P, Hollak C, Van Eysden-Plaisier M, et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000;23:77-82
  • Mistry PK, Sadan S, Yang R, et al. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists–oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 2007;82:697-701
  • Lee RE. The pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowski GA, editors, Gaucher disease: a century of delineation and research. New York: Liss; 1982. p. 177-217
  • Fleshner PR, Aufses Jr AH, Grabowski GA, et al. A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 1991;161:69-75
  • Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-8
  • Grabowski GA, Leslie N, Wenstrup RJ. Enzyme therapy in Gaucher disease: the first five years. Blood Rev 1998;12:115-33
  • Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20
  • Weinreb NJ, Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005;80:223-9
  • Davies EH, Erikson A, Collin-Histed T, et al. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 2007;30:935-42
  • Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucerebrosidase for Gaucher disease. N Engl J Med 1991;324:1464-70
  • Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9
  • Charrow J, Dulisse B, Grabowski GA, et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71:205-11
  • Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy on bone mineral density in type 1 Gaucher disease. J Bone Miner Res 2007;22:119-26
  • Prows CA, Sanchez N, Daugherty C, Grabowski GA. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997;71:16-21
  • Elstein D, Abrahamov A, Zimran A. Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin Genet 1998;54:179-84
  • Weinreb NJ, Brady RO, Tappel AL. The lysosomal localization of sphingolipid hydrolases. Biochim Biophys Acta 1968;159:141-6
  • Vaccaro AM, Salvioli R, Barca A, et al. Structural analysis of saposin C and B. J Biol Chem 1995;270:9953-60
  • Christomanou H, Kleinschmidt T, Braunitzer G. N-Terminal amino-acid sequence of a sphingolipid activator protein missing in a new human Gaucher disease variant. Biol Chem Hoppe Seyler 1987;368:1193-6
  • Tylki-Szymanska A, Czartoryska B, Vanier M-T, et al. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet 2007;72:538-42
  • Brady RO. Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem 1967;13:565-77
  • Pentchev PG, Brady RO, Hibbert SR, et al. Isolation and characterization of glucocerebrosidase from human placental tissue. J Biol Chem 1973;248:5256-61
  • Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in the Gaucher disease. N Engl J Med 1974;291:989-93
  • Furbish FS, Steer CJ, Barranger JA, et al. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and kupffer cells. Biochem Biophy Res Commun 1978;81:1047-53
  • Brady RO, Murray GJ, Baron NW. Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis 1994;17:510-9
  • Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-63
  • Jayapal KP, Wlaschin KF, Hu W-S, et al. Recombinant protein therapeutics from CHO cells – 20 years and counting. Chem Eng Prog 2007;103:40-7
  • Dingerman T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J 2008;3:90-7
  • Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9
  • Genzyme website. Available from: http://www.cerezyme.com/global/pi.pdf [Last accessed 20 June 2008]
  • Mistry PK, Wraight, EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996;348:1555-9
  • Zimran A, Hollak CE, Abrahamov A, et al. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993;82:1107-9
  • Milligan A, Bruce R, Freud C, et al. Compliance with home treatment using enzyme replacement therapy for type 1 Gaucher disease: a UK centres perspective. Haematologica 2007;92(Suppl 1):222
  • Milligan A, Hughes D, Goodwin S, et al. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006;15:330-3
  • Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess 2006;10:iii-iv, ix-136
  • Giraldo P, Solano V, Perez-Calvo J-I, et al. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005;14:453-61
  • Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;71:576-88
  • Packman W, Wilson Crosbie T, Riesner A, et al. Psychological complications of patients with Gaucher disease. J Inherit Metab Dis 2006;29:99-105
  • Mankin HJ, Trahan CA, Barnett NA, et al. A questionnaire study for 128 patients with Gaucher disease. Clin Genet 2006;69:209-17
  • Garber AM. No price too high? N Engl J Med 1992;327:1676-8
  • Moscicki RA, Taunton-Rigby A. Treatment of Gaucher's disease. N Engl J Med 1993;328:1564; author reply 1567-8
  • Beutler E. Economic malpractice in the treatment of Gaucher's disease. Am J Med 1994;97:1-2
  • Elstein D, Hadas-Halpern I, Itzchaki M, et al. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 1996;22:104-11; discussion 112-4
  • Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73:430-40
  • De Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006;108:830-5
  • Lebel E, Dweck A, Foldes AJ, et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004;22:597-601
  • Schiffmann R, Mankin H, Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28:288-96
  • Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003;19:395-414
  • Kelly C, Bartholomew P, Lapworth A, et al. Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 2002;13:423
  • Robinson RJ, Al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-6
  • Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41(S5):15-22
  • Vom Dahl S, Poll L, Di Rocco M, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 2006;22:1045-64
  • Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163:58-66
  • Andersson H, Kaplan P, Kacena K, et al. Eight-year clinical outcomes of long-term enzyme replacement therapy in 884 children with type 1 Gaucher disease. Pediatrics 2008; In press
  • Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629-37
  • Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-53
  • Andersson HC, Charrow J, Kaplan P, et al. For the International Collaborative Gaucher Group US Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-10
  • Azuri J, Elstein D, Lahad A, et al. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test 1998;2:297-9
  • Food And Drug Administration: Cerezyme prescribing data. Available from: http://www.fda.gov/cder/foi/label/2002/20367slr055_Cerezyme_lbl.pdf [Last accessed 9 July 2007]
  • European Agency For The Evaluation Of Medicinal Products: Cerezyme prescribing data. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/H-157-PI-en.pdf [Last accessed 9 July 2007]
  • Elstein D, Granovsky-Grisaru S, Rabinowitz R, et al. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997;177:1509-12
  • Aporta Rodrigues R, Escobar Vedia JL, Navarro Castro AM, et al. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica 1998;83:852-3
  • Cleary JE, Burke WM, Baxi LV. Pregnancy after avascular necrosis of the femur complicating Gaucher's disease. Am J Obstet Gynecol 2001;184:233-4
  • Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004;190:435-41
  • Cox TM, Aerts JMFG, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; May 23 [Epub ahead of print]
  • Ioscovich A, Elstein Y, Halpern S, et al. Anesthesia for obstetric patients with Gaucher disease: survey and review. Int J Obstet Anesth 2004;13:244-50
  • Lonser RR, Walbridge S, Murray GJ, et al. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol 2005;57:542-8
  • Erikson A, Bembi B, Schiffmann R. Neuronopathic forms of Gaucher's disease. Baillieres Clin Haematol 1997;10:711-23
  • Vellodi A, Bembi B, De Villemeur T, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001;24:319-27
  • Zimran A, Elstein D. No justification for very high-dose enzyme therapy for patients with type III Gaucher disease. J Inherit Metab Dis 2007;30:843-4
  • Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 2006;88:208-15
  • Figueroa ML, Rosenbloom BE, Kay AC. A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992;327:1632-6
  • Hollak CE, Aerts JMFG, Goudsmit R, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 1995;345:1474-8
  • Elstein D, Abrahamov A, Hadas-Halpern I, et al. Low-dose low frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type 1 Gaucher disease. Q J Med 1998;91:483-8
  • Heitner R, Arndt S, Levin JB. Imiglucerase low-dose therapy for paediatric Gaucher disease – a long-term cohort study. S Afr Med J 2004;94:647-51
  • Cohen IJ, Katz K, Kornreich L, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises with severe juvenile onset type 1 Gaucher disease. Blood Cells Mol Dis 1998;24:296-302
  • Wilson C, Spearing R, Teague L, et al. The outcome of clinical parameters in adults with severe type 1 Gaucher disease using very low dose enzyme replacement therapy. Mol Genet Metab 2007;92:131-6
  • Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41(Suppl 5):4-14
  • Elstein D, Abrahamov A, Hadas-Halpern I, et al. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000;110:488-92
  • Weinreb NJ. Interruption in enzyme replacement therapy for Gaucher disease. Br J Haematol 2001;113:1087-9
  • Grinzaid KA, Geller E, Hanna SL, et al. Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002;4:427-33
  • Toth J, Erdos M, Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003;70:125-8
  • Drelichman G, Ponce E, Basack N, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151:197-201
  • Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007;110:2296-301
  • Weinreb N. Effect of enzyme replacement therapy with imiglucerase (Cerezyme) every 4 weeks in patients with type I Gaucher disease. Mol Genet Metab 2008;93:S41
  • Rosenberg MA, Kingma W, Fitzpatrick MA, et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-8
  • Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998;351:1544-6
  • Rosengarten D, Abrahamov A, Nir A, et al. Outcome of ten years' echocardiographic follow-up in children with Gaucher disease. Eur J Pediatr 2007;166:549-51
  • Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004;75:641-53
  • Cox TM, Aerts JM, Andria G, et al.; Advisory Council to the European Working Group on Gaucher disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26(6):513-26
  • Pastores GM, Elstein D, Hrebicek M, et al. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 2007;29:1645-54
  • Giraldo P, Latre P, Alfonso P, et al. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. Haematologica 2006;91:703-6
  • Actelion website. Available from: http://www.actelion.com/uninet/www/www_main_p.nsf/Content/Development+Zavesca%C2%AE+%28miglustat%29 [Last accessed 1 February 2008]
  • Zimran A, Loveday K, Fratazzi C, et al. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2007;39:115-8
  • Zimran A, Bhirangi K, Mensah R, et al. (118) 36 months on treatment: open-label phase I/II long-term study of enzyme replacement therapy (ERT) with ‘gene-activated’ human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease. Mol Genet Metab 2008;93:S45
  • Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007;5:579-90
  • Aviezer D, Almon-Brill E, Shaaltiel Y, et al. Novel enzyme replacement therapy for Gaucher disease: on-going phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Mol Genet Metab 2008;93:S15
  • Peterschmidtt J, Lukina E, Watman N, et al. Preliminary results of a phase 2 clinical trial of Genz-112638 in patients with type 1 Gaucher disease. Mol Genet Metab 2008;93:32-3
  • Street RA, Chung S, Wustman B, et al. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006;103:13813-8
  • Wustman B, Pine C, Ranes B, et al. Pharmacological chaperone therapy for Gaucher disease: mechanism of action, a survey of responsive mutations and phase I clinical trial results. Mol Genet Metab 2008;93:S44
  • Weinreb N, Eng C, Fernhoff P, et al. A phase 2 clinical trial of the pharmacological chaperone AT2101 for the treatment of Gaucher disease. Presented at the annual meeting of the American College of Clinical Genetics; 12 – 16, March 2008; Phoenix, Arizona. Available from: http://submissions.miracd.com/SecureView/ACMG/9umloo9806tca2s5ger6.pdf [Last accessed 18 March 2008]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.